




Searching News Database: haemophilia A
HSMN NewsFeed - 19 Jun 2024
European Commission grants Sobi(R) Marketing Authorisation for ALTUVOCT(TM) for treatment of haemophilia A
European Commission grants Sobi(R) Marketing Authorisation for ALTUVOCT(TM) for treatment of haemophilia A
HSMN NewsFeed - 13 Nov 2018
Sobi(TM) to Acquire Synagis(R) US Rights From AstraZeneca - Creates a Platform for Global Growth
Sobi(TM) to Acquire Synagis(R) US Rights From AstraZeneca - Creates a Platform for Global Growth
HSMN NewsFeed - 22 Aug 2018
Sobi(TM) Appoints Anne Marie de Jonge Schuermans as Head of Technical Operations
Sobi(TM) Appoints Anne Marie de Jonge Schuermans as Head of Technical Operations
HSMN NewsFeed - 16 Apr 2018
Apitope Announces Positive Results with Novel Treatment for Graves' Disease
Apitope Announces Positive Results with Novel Treatment for Graves' Disease
HSMN NewsFeed - 16 Jan 2017
European Commission Amends Marketing Authorisation for RUCONEST(R) to Include Self-Administration
European Commission Amends Marketing Authorisation for RUCONEST(R) to Include Self-Administration
HSMN NewsFeed - 11 Nov 2016
CHMP Adopts Positive Opinion to Include Self-administration for RUCONEST(R)
CHMP Adopts Positive Opinion to Include Self-administration for RUCONEST(R)
HSMN NewsFeed - 13 May 2016
Alprolix(R) (rFIXFc) approved in the EU for the treatment of haemophilia B
Alprolix(R) (rFIXFc) approved in the EU for the treatment of haemophilia B
HSMN NewsFeed - 24 Nov 2015
Sobi and Biogen’s ELOCTA(R) (rFVIIIFc) Approved in Europe for the Treatment of Haemophilia A
Sobi and Biogen’s ELOCTA(R) (rFVIIIFc) Approved in Europe for the Treatment of Haemophilia A
HSMN NewsFeed - 24 Mar 2014
Health Canada Approves Biogen Idec's Long-Acting ALPROLIX(TM) Therapy for Hemophilia B
Health Canada Approves Biogen Idec's Long-Acting ALPROLIX(TM) Therapy for Hemophilia B
HSMN NewsFeed - 11 Mar 2009
European Commission Approves ReFacto AF(TM) as a Variation to the Refacto(R) Marketing Authorisation
European Commission Approves ReFacto AF(TM) as a Variation to the Refacto(R) Marketing Authorisation
HSMN NewsFeed - 15 Dec 2006
Lipoxen Announces $75M Agreement With Baxter to Develop New Blood Clotting Factors
Lipoxen Announces $75M Agreement With Baxter to Develop New Blood Clotting Factors
Additional items found! 2

Members Archive contains
2 additional stories matching:
haemophilia A
(Password required)
haemophilia A
(Password required)